BioCentury
ARTICLE | Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

April 16, 2020 1:18 AM UTC
Updated on Apr 16, 2020 at 4:01 AM UTC

TScan, Novartis partner to develop TCR therapies
TScan Therapeutics Inc. entered an agreement with Novartis AG (NYSE:NVS; SIX:NOVN) to discover and develop TCR-engineered T cell therapies. Novartis will pay a technology access fee and research funding totaling $30 million, and TScan is eligible for “hundreds of millions of dollars” in milestone payments and mid-single to low double-digit royalties on net sales for each product.

TScan will identify and characterize TCRs using its peptidome screening platform, and Novartis has the option to license and develop TCRs for up to three targets, as well as rights of first negotiation for additional targets and TCRs that arise under the deal (see “TScan: Tracking Down Novel T Cell Targets”)...